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background:  The appropriate duration of dual antiplatelet therapy (DAPT) after drug-eluting stents (DES) is an area of current investigation. 
Given that longer treatment has been associated with an increased risk of bleeding while benefit remains uncertain, we sought to determine what 
magnitude of benefit would be required to warrant longer durations of DAPT.
methods: We developed a decision analytic Markov model comparing varying DAPT durations: 6, 12, and 30 months after DES. Published studies 
were used to derive the model probabilities for stent thrombosis (ST), myocardial infarction (MI), cardiac and non-cardiac death, major and minor 
bleeding, and hemorrhagic and ischemic stroke. We used sensitivity analyses to identify the incremental benefit of longer DAPT duration on either 
ST or the composite of cardiac death, myocardial infarction and ischemic stroke (MACCE) that would be required to outweigh the increased risk of 
bleeding associated with longer DAPT in terms of quality-adjusted life expectancy. 
results: The relative risk reduction in ST alone, MACCE alone, or both ST + MACCE that would be required to outweigh the excess bleeding risk 
associated with longer DAPT therapy are provided in Table 1. 
Conclusions: Small reductions in the risk of ischemic events are sufficient to outweigh the known bleeding risk associated with DAPT. Therefore, 
adequately powered randomized trials are required to determine whether an overall benefit with longer DAPT is present. 
Table 1: RRR in ischemic events that would outweigh increased risk of bleeding with longer DAPT
Ischemic Event RRR 12 vs. 6m DAPT RRR 30 vs. 12m DAPT
Stent thrombosis (ST) alone 11% 28%
MACCE alone 2.2% 6.4%
Both ST + MACCE 1.8% 5.4%
